Rx Prescription Required
Classes: Pediculicides, Metalloproteinase Inhibitors
Uses: Treatment of head lice infestation
Administration: Topical
Dosages ›
Interactions ›
Adverse Effects ›
Warnings ›
Safety Advice ›
Pharmacology ›
General Considerations ›
Xeglyze
Manufacturer: Dr Reddy’s Laboratories
Salt Composition: Abametapir (0.74% lotion)
Price: NA
No drug combination found
Dosages
Dosage Forms & Strengths: topical lotion (0.74%)
Indicated for topical treatment of head lice infestation
Apply to dry hair in an amount sufficient (up to the full content of one bottle) to thoroughly coat the hair and scalp. Use in the context of overall lice management program.
Dosage Forms & Strengths: topical lotion (0.74%)
Indicated for topical treatment of head lice infestation in children and adolescents aged ≥6 months
Apply to dry hair in an amount sufficient (up to the full content of one bottle) to thoroughly coat the hair and scalp
<6 months: Safety and efficacy not established
Interactions
For 2 weeks of Abametapir application, avoid taking drugs that are substrates of CYP3A4, CYP2B6 or CYP1A2
Adverse Effects
- Erythema (4%)
- Rash (3.2%)
- Scalp erythema/edema (3.2%)
- Skin burning sensation (2.6%)
- Vomiting (1.7%)
- Contact dermatitis (1.7%)
- Scalp pruritus (1.4%)
- Eye irritation (1.2-1.7%)
- Hair color changes (1%)
Contraindications & Warnings
- Risk of Neonatal Benzyl Alcohol Toxicity: Systemic exposure to benzyl
alcohol has been associated with serious adverse reactions and death in
neonates and low birth-weight infants. - Safety and effectiveness in pediatric patients below the age of 6 months have not been established. Use is not recommended in pediatric patients under 6 months of age because of the potential for increased systemic absorption.
- Risk of Benzyl Alcohol Toxicity from Accidental Ingestion: Administer
only under direct supervision of an adult.
Safety Advice
🍺 Alcohol: Caution
🤰🏻 Pregnancy: Insufficient human data
🤱🏻 Breastfeeding: Insufficient human data
🚗 Driving: Safe
Kidney: Safe
Liver: Safe
Pharmacology
Mechanism of Action: Abametapir is a novel pediculicidal metalloproteinase inhibitor. Metalloproteinases have a role in physiological processes critical to egg development and survival of lice
Absorption
- Peak plasma time: 0.57-1.54 hr
Peak plasma concentration
- 6 months to <1 year: 228-418 ng/mL
- 1 to <2 years: 147-209 ng/mL
- 2 to <3 years: 160-206 ng/mL
- 3 to 17 years: 52-121 ng/mL
AUC
- 6 months to <1 year: 688-1057 ng⋅hr/mL
- 1 to <2 years: 406-446 ng⋅hr/mL
- 2 to <3 years: 602-633 ng⋅hr/mL
- 3 to 17 years: 194-330 ng⋅hr/mL
Distribution: Protein-bound Abametapir: 91.3-92.3%, Abametapir carboxyl (metabolite): 96-97.5%
Metabolism: Extensively metabolized, primarily by CYP1A2 to a mono-hydroxylated metabolite (abametapir hydroxyl) and further to a mono-carboxylated metabolite (abametapir carboxyl)
Elimination: Excretion of abametapir and its human metabolites was not examined
Half-life (adults): 21 hr; ~71 hr or longer (abametapir carboxyl)
General Considerations
Inform the patient and caregiver of the following instructions
- Do not ingest.
- Keep out of reach of children.
Use in Specific Populations
• Avoid contact with eyes.
• Wash hands after application.
• Hair may be shampooed any time after the treatment.
• Treatment with abametapir involves a single application. Do not re-treat.
• Discard any unused portion. Do not flush contents down sink or toilet.
Report an error